Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

AbbVie Shares Surge 4.66% in Three Days, Emrelis Approval Boosts Oncology Segment to 66th in Trading Volume

Market BriefMonday, May 19, 2025 8:00 pm ET

1min read

AbbVie (ABBV) shares rose 0.92% on May 19, 2025, marking the third consecutive day of gains, with a total increase of 4.66% over the past three days. The company's trading volume reached $964 million, placing it 66th in the day's trading rankings.

The U.S. Food and Drug Administration (FDA) has approved AbbVie's Emrelis (telisotuzumab vedotin-tllv) for the treatment of adults with previously treated advanced non-small cell lung cancer (NSCLC) who exhibit high c-Met protein overexpression. This approval makes Emrelis the first and only treatment available for this specific patient population, who often face a poor prognosis and limited treatment options.

This approval is a significant milestone for AbbVie, as it expands the company's portfolio of oncology treatments and reinforces its commitment to developing innovative therapies for patients with high unmet medical needs. The approval of Emrelis is expected to drive growth in AbbVie's oncology segment and contribute to the company's overall revenue.

However, AbbVie is also facing legal challenges related to its investment in Cerevel Therapeutics Holdings, Inc. Several law firms have announced class action lawsuits on behalf of shareholders who have suffered losses due to alleged misrepresentations and omissions by the company. The lead plaintiff deadline for these lawsuits is June 3, 2025.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.